

Recommendations

In this guide

[In this guide](#)

1. [Novel Formulations of Supplement Compounds Designed to Increase Oral Bioavailability](#)
2. [Novel Formulations of Supplement Compounds Designed to Increase Oral Bioavailability - Executive Summary](#)
3. [Physical-chemical properties of novel bioavailable supplement formulations](#)
4. [Mechanisms of increased bioavailability](#)
5. [COT's discussion](#)
6. [Physical-chemical properties of novel bioavailable supplement formulations - Conclusions](#)
7. [Physical-chemical properties of novel bioavailable supplement formulations - Recommendations](#)
8. [Annex A - Discussion Paper on Novel Formulations of Supplement Compounds Designed to Increase Oral Bioavailability](#)
9. [Annex A - Novel formulations of supplement compounds](#)
10. [Annex A - Lipid-based delivery systems](#)
11. [Annex A - Other systems to increase bioavailability](#)
12. [Annex A - Uncertainties surrounding novel supplement formulations](#)
13. [Annex A -Market data and projected trends](#)
14. [Annex A - Case studies of supplement formulations with increased bioavailability](#)
15. [Annex A - Summary and discussion](#)
16. [Annex A - Questions for the Committee](#)
17. [Annex A - Abbreviations and glossary](#)
18. [Annex A - Glossary](#)
19. [Annex A- References](#)
20. [Appendix A: Literature search for specific toxicology studies with novel supplement formulations](#)

- 1.** Novel formulations and their associated active agents should be assessed for their toxicokinetics on a case-by-case basis.
- 2.** The model systems used to assess alterations in toxicokinetics should consider species differences with respect to metabolism.
- 3.** The effect of the feeding state (fed vs. fasted) is a key determinant of bioavailability and must be critically considered when comparing across different formulations.
- 4.** The suitability of acceptable daily intakes (ADIs) and other health-based guidance values (HBGVs) for an unformulated supplement for characterising the risk from that supplement formulated to increase its bioavailability should always be considered.
- 5.** There are a number of approaches that can be used to consider how HBGVs relate to differences in bioavailability, and these should be assessed and utilised on a case-by-case basis.